miv-cel (KYV-101) — Topline data
Q3 2026
Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026Source filing
KYTX biotech catalysts & pipeline
KYVERNA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
miv-cel (KYV-101) — Full data
H2 2026
The Company will share one-year follow-up data in the second half of 2026, which is expected to further demonstrate miv-cel's durable treatment effect.Source filing
miv-cel (KYV-101) — Initial data
Q4 2026
Kyverna expects to provide an update on its PMS development strategy by early 2027, as well as additional data from the Stanford Phase 1 IIT in Q4 2026.Source filing
miv-cel (KYV-101) — NDA/BLA submission
Q4 2026
On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026Source filing
miv-cel (mivocabtagene autoleucel) — Conference presentation
2026
o Lupis Nephritis: Report Phase 1 data in a peer-reviewed publication in 2026Source filing